Sales of generic drugs under PMBJP at Rs 814 crores this fiscal year so far: Government

0

Read the article

Sales of affordable quality generic drugs under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) amounted to Rs 814.21 crore in the current financial year resulting in estimated savings of around Rs 4,800 crore for the citizens, Dr. Mansukh Mandaviya, Minister of Health, Rajya Sabha informed yesterday .

In a statement laid on the table in the Upper House, the Union Minister said that the PMBJP was launched with the aim of making quality generic medicines accessible to all at affordable prices with dedicated outlets open for this purpose.

Under this program, until February 28, 2022, approximately 8,689 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJK) were opened, covering all districts in the country, he added.

Emphasizing that the Jan Aushadhi the drugs are 50-90% cheaper than market prices of brand name drugs, Mandaviya said, “In the current financial year (till 28 Feb 2022), total sales of Rs 814.21 crores have been made, which has led to an estimated savings of around Rs 4,800 crores for citizens.In a written response to another question, the minister said: , the PMBJP achieved a sale of Rs 665.83 crores in the financial year 2020-21, saving the citizens about Rs 4,000 crores from branded drugs. PMBJP currently includes 1,616 drugs and 250 surgical items covering all major therapeutic groups such as cardiovascular, anti-cancer, anti-diabetic, anti-infective, anti-allergy, gastrointestinal and nutraceutical drugs, among others, he said. in a response to another request .

The government’s effort is to improve the product basket of generic drugs and surgical products. This is an ongoing process based on feedback from various stakeholders and market demands, he added.

Responding to another question, Mandaviya said, “The government has set a target to have about 10,500 PMBJK by March 2025 nationwide. The goal for the year 2022-23 is to have around 9,300 PMBJK across the country.

Edited by EP News Bureau

Share.

About Author

Comments are closed.